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Introduction
Purulent pericarditis (PP) usually occurs in the 
compromised host [1]. Predisposing factors have changed 
over time. Pneumonia was the primary source of infec-
tion for the majority of patients (72%) in the pre-
antibiotic era, compared with only 22% of patients in the 
post-antibiotic era [2]. Nowadays, most cases of PP are 
healthcare associa  ted. Bloodstream infections or under-
lying non-infectious conditions such as thoracic surgery, 
chronic kidney disease, immunosuppression, or malig-
nancy (Table 1) are new predisposing factors.
Despite medical progress, PP is still associated with 
high mortality (20 to 30%) attributed to both early and 
late complications, namely persistent PP and constrictive 
pericarditis [1,2]. Th  ese late complications may be 
prevented by early pericardiectomy, a surgical procedure 
known for its potential morbidity. Twenty years ago, 
intrapericardial ﬁ   brinolysis emerged as a promising 
alternative to surgery. Nevertheless, there is no consensus 
about its indication.
Th   e history, pathophysiology, complications and 
surgical management of PP are described. In light of the 
physiological and histological data, we review the 
rationale of ﬁ  brinolysis in PP, the evidence for its eﬃ   cacy, 
and all publications on indications, timing, results, and 
complications.
Methods
We searched for reported case series of PP managed with 
ﬁ  brinolysis. We reviewed the MEDLINE database since 
1951. Th   e following keywords were used: ‘purulent peri-
carditis’, ‘infectious pericarditis’, ‘constrictive peri  carditis’, 
‘ﬁ  brinolysis’, ‘streptokinase’ (SK), ‘urokinase’ (UK), ‘tissue 
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© 2011 BioMed Central Ltdplasminogen activator’ (tPA), and ‘peri  carditis’. We 
reviewed only English-language literature. We found 134 
cases includ  ing 94 cases reported in one single study, 
providing pooled results of 60 tuberculous pericarditis 
patients and 34 PP patients. As patients with tuberculous 
pericarditis were excluded, only 74 cases were ﬁ  nally 
considered. As the speciﬁ  c out  come of the 34 PP cases 
was not available, our outcome analysis only focused on 
the 40 remaining cases [3].
Information related to modalities of administration, 
complications, and outcome of ﬁ  brinolysis was collected.
Defi  nitions and aetiologic classifi  cation
PP is deﬁ   ned as a neutrophilic pericardial eﬀ  usion 
infected by a bacterial, fungal, or parasitic agent. Tuber-
culous pericarditis is a lymphocytic eﬀ  usion.  Classiﬁ  -
cation of PP comprises ﬁ  ve aetiologic entities (Table 1) 
[1,4]. Th  e advent of antibiotics has changed epidemio-
logical and aetiopathogenic features. Th   e median age of 
patients has increased from 21 to 49 years [2], whereas 
the overall frequency of PP has decreased. Before the 
antibiotic era, PP accounted for 40% of all cases of acute 
pericarditis and was related to the contiguous spread of 
lung infections in 72% of cases. Nowadays, pneumonia 
remains the primary source of infection in only 22% of 
cases while PP is mainly associated with healthcare and 
bloodstream infections [1,2,5]. For instance, oesophageal 
and cardiothoracic surgeries can be responsible for the 
direct inoculation of the pericardial space whereas 
immunosuppressive therapy, dialysis, and chemotherapy 
are relatively recent predisposing conditions [2,4].
Diagnosis
Th   e only way to diagnose PP is to obtain pericardial ﬂ  uid 
for microbiological culture and direct microscopic 
exami  nation. In a context of pneumonia, transthoracic 
echocardiography or computed tomography scan of the 
chest may disclose complications such as pleural 
empyema or pericardial eﬀ  usion [6,7] (Figure 1). Interest-
ingly, PP may have an insidious presentation without 
pericardial signs until occurrence of cardiac tamponade 
[2,4,8,9] (Table 2). Indeed, in a postmortem series by 
Klacs  mann and colleagues, among 55 cases of PP only 10 
cases had been suspected and diagnosed ante mortem 
[1]. Poor diagnostic performance of the condition results 
in late diagnosis, at an advanced stage, after onset of 
pericardial adhesions [10].
Complications
PP may lead to cardiac tamponade and septic shock. Th  e 
treatment of these conditions has no speciﬁ  city. On the 
contrary, constrictive pericarditis and persistent PP – 
two late-stage complications – imply speciﬁ  c considera-
tions and management [1,4].
Constrictive pericarditis is deﬁ  ned by the thickening 
and fusion of the pericardium causing low pericardial 
com  pliance and right heart failure. Haemodynamic 
compro  mise and low cardiac output may ensue because 
of adiastoly or impaired cardiac ﬁ  lling. Pericardial ﬁ  brosis 
is caused by chronic/subacute inﬂ  ammation  inducing 
ﬁ   bro  blast proliferation and collagen deposition. Two 
large reviews found the same frequency of 3.5% for 
Table 1. Classifi  cation of purulent pericarditis according to 
source of infecting organism
I  Infection by contiguous spread from a pleural, mediastinal or pulmonary 
 focus 
II  Infection by contiguous spread of intracardiac infection
III  Infection following systemic bacteraemia 
IV  Infection with contiguous spread from a postoperative infection
V  Infection following a subdiaphragmatic suppurative lesion
Table 2. Clinical features and complications of purulent 
pericarditis (from [2])
Clinical feature 
  Duration of symptoms before presentation (days)  7 ± 3
 Chest  pain  31
 Fever  85
  Pericardial friction rub  33
 Electrocardiographic  abnormalities  45
Complication 
 Death  29
 Cardiac  tamponade  15
Data presented as mean ± standard deviation or percentage. 
Figure 1. Computed tomography scan showing complications 
of pneumonia. Chest computed tomography scan of a patient 
with left alveolar pneumonia, complicated by empyema (E) and 
circumferential pericardial eff  usion (PE). R, right; L, left.
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one smaller study with long-term follow-up, however, 
constrictive pericarditis occurred in 57% of cases, with 
few cases occurring during the ﬁ  rst year.
We propose an original deﬁ   nition for persistent PP. 
Th   is entity is deﬁ  ned by a chronic or recurrent purulent 
pericardial eﬀ   usion occurring despite drainage and 
adequate antibiotherapy. Th   is feature is well described in 
case reports. Persistence of PP is associated with occur-
rence of pericardial adhesions and loculation of peri-
cardial eﬀ  usion due to the presence of thick ﬁ  brin clots 
preventing complete evacuation of pus through peri-
cardial drains or pericardiostomy [12-17]. Purulent dis-
charge persists during several weeks and may lead to 
death due to septic shock or tamponade. At the stage of 
persistent PP, pericardiectomy is challenging and asso-
ciated with high morbidity because of pericardial adher-
ences and areas of fusion. Moreover, patients present 
with impaired general status [12-17]. Interestingly, this 
entity has not been previously deﬁ  ned or classiﬁ  ed as a 
late complication of PP, resulting in a lack of epidemio-
logical data. Finally, because of chronic inﬂ  ammation, 
persistent PP may promote constrictive pericarditis. 
Nevertheless, these two entities have distinct clinical and 
pathophysiological features.
Pathophysiology of purulent pericarditis and of its 
complications
PP shares pathophysiological similarities with empyema. 
In the case of empyema, the contiguous spread of pneu-
monia causes pleural mesothelial barrier dysfunction 
leading to exudative pleural eﬀ  usion [18]. Th  e second 
step is bacterial invasion, which attracts leucocytes. 
Activated leucocytes promote coagulation, resulting in 
ﬁ  brin formation [19]. Fibrin deposits are responsible for 
pleural adhesion, thickening, and loculation of eﬀ  usion, 
therefore preventing easy drainage and antibiotic diﬀ  u-
sion. When the process is prolonged, inﬂ  ammation leads 
to ﬁ  brosis due to collagen secretion.
Experimental models argue for a similar patho-
physiological process in PP, leading from pericardial 
inﬂ  am  mation to pericardial adhesion and ﬁ  brosis [20,21]. 
Th  ese studies indicate that pericardial loculation and 
intra pericardial  ﬁ  brosis may occur respectively 1 week 
and 2 weeks after onset of the disease [20,21].
Furthermore, these studies show that ﬁ  brin formation 
is the cornerstone in the pathogenesis of both persistent 
PP and constrictive pericarditis. Fibrin may thus be a 
target in the management of PP.
General management, surgery and fi  brinolysis
General medico-surgical management
Management of PP requires a combined surgical and 
medical approach with complete drainage of the eﬀ  usion 
and complementary antibiotherapy. Antibiotic regi  men is 
initially empirical and should target Staphylo coccus  aureus. 
Anaerobes and Gram-negative bacteria should be targeted 
in case of a digestive origin [22,23]. In recently hospitalised 
patients, methicillin-resistant Staphylo  coccus should be 
considered [23]. Considering the lack of guidelines on the 
duration of antibiotherapy in PP and by analogy with 
empyema, a treatment of at least 3 weeks seems reason-
able [24]. Moreover, antibiotherapy should be maintained 
until removal of the focus of infection, and until 
improvement of clinical and biological signs.
Surgery
Until 1941 the mortality of PP was estimated to be 100% 
in untreated cases. Pericardiostomy decreased mortality 
to about 50%, and to 30% when associated with 
antibiotics [17]. Eradication of infected pericardial ﬂ  uid 
is the cornerstone of PP therapy, although the way to 
obtain eradication remains controversial (Table 3) [25]. 
Guidelines from the European Society of Cardiology 
make the following statement: ‘Frequent irrigation of the 
pericardial cavity with UK or SK, using large catheters, 
may liquefy the purulent exudate, but open surgical 
drainage through subxiphoid pericardiotomy is prefer-
able’ [26]. Because of loculations and adhesions, simple 
evacuation by surgical or percutaneous drainage may not 
prevent constrictive pericarditis or persistent PP [25,27-29]. 
To avoid these complications, invasive surgical treat  ment 
has been advocated. In a retrospective series, partial 
pericardial resection or total pericardiectomy seem to be 
associated with a better outcome than simple pericardial 
drainage [4,10,25,27,29] (Table 4). Taken together these 
studies suggest a curative role of pericardiectomy by 
achieving complete eradication of the infection and a role 
in preventing persistent PP and constrictive peri  carditis.
Despite these convincing data, physicians are reluctant 
to perform preventive surgery associated with potential 
serious complications. Nevertheless, this procedure could 
be easier early in the disease, before apparition of 
adhesions. Furthermore, operative mortality is related to 
the preoperative disability of patients [30,31] and haemo-
dynamic compromise is rarely observed at an early stage. 
Table 3. Diff  erent surgical modalities for pericardial 
eff  usion evacuation
I  Subxiphoid percutaneous catheter 
II  Subxiphoid tube drain
III  Subxiphoid tube or percutaneous catheter and fi  brinolysis 
IV  Pericardial window and pleural drain
V  Partial pericardiectomy with pericardial tube
VI  Anterior interphrenic pericardiectomy
VII Total  pericardiectomy
Adapted from [25].
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preventive pericardiectomy [32].
Fibrinolysis
Intrapericardial ﬁ   brinolysis, a less invasive procedure, 
has been proposed as an alternative to surgery for PP 
management. Th  e objective of ﬁ   brinolysis is to target 
ﬁ  brin formation, to optimise evacuation of a thick ﬂ  uid, 
and therefore to prevent both persistent PP and 
constrictive pericarditis.
Rationale of intrapericardial fi  brinolysis
Fibrinolysis in PP follows the same rationale as that in 
empyema. In the latter, surgery also has better results 
than simple drainage. Many authors have attempted to 
demonstrate the eﬃ   cacy of intrapleural ﬁ  brinolysis com-
pared with simple drainage for prevention of persistent 
empyema requiring surgical debridement. Eﬃ   cacy  of 
ﬁ  brinolysis was demonstrated in a randomised controlled 
trial (RCT) and a meta-analysis [33,34]. In a double-blind 
RCT including 44 patients, Diacon and colleagues found 
a better clinical outcome and fewer referrals to surgery in 
the SK group [33]. Unexpectedly, the largest RCT testing 
the eﬃ   cacy of SK in empyema did not ﬁ  nd any signiﬁ  cant 
diﬀ  erence between both groups [35]. Th  e group of 208 
patients assigned to SK treatment had the same rate of 
referrals to surgery as the group of 222 patients who 
received normal saline. Th   e population of this study was 
heterogeneous and the timing of ﬁ   brino  lysis was late, 
however, suggesting that ﬁ  brinolysis may still be useful in 
subgroups of younger patients treated earlier.
Evidence of pericardial fi  brinolysis effi   cacy
Given the similarities between empyema and PP, ﬁ  brino-
lysis has been considered in PP. Th  e  ﬁ  rst cases of success-
ful management of PP with ﬁ  brinolysis were reported in 
1951 [12,14]. Th  ese patients had chronic PP persisting 
and relapsing despite pericardiostomy and antibiotics. 
Fibrino  lysis was successfully administered at a late stage 
as a rescue treatment, allowing complete evacuation of 
purulent material. Forgotten for 30 years, the treatment 
was rediscovered in 1984 by Bennett [13]. Eﬃ   cacy  of 
ﬁ   brinolysis was also demonstrated in an experimental 
model of acute pericarditis in dogs [21]. Fibrinolysis 
or normal saline was applied through a pericardial drain 
daily from the third through sixth day after instillation of 
the irritant mixture. Clinical and histological patterns of 
constrictive peri  carditis were evaluated over a 60-day 
period. All 11 animals assigned to the normal saline group 
developed pericardial thickening and adhesions. Among 
these, nine animals demonstrated clinical features of 
constrictive pericarditis. One-half of the 10 animals in the 
UK group did not demonstrate any sign of constriction or 
any histological changes of the pericardium.
Clinical data on ﬁ  brinolysis in PP exist. All cases of 
ﬁ  brinolysis in PP available in the English-language litera-
ture are summarised in Table 5. Th  ere is great hetero-
geneity in the diﬀ   erent protocols used. Among 40 
analysable cases, we found two cases of failure requiring 
pericardiectomy with a favourable outcome. Out of two 
described deaths, only one was due to PP. No sign of 
clinical constriction at hospital discharge was observed 
for the 35 remaining patients (data not provided for three 
patients). During follow-up, no constriction was found in 
patients for whom data were available (20 patients on 
clinical examination and 12 patients on transthoracic 
echocardiography).
One RCT with long-term follow-up (mean 57 ± 29 
months) assessed the eﬃ   cacy of ﬁ  brinolysis in PP [3]. Un-
fortunately, the study population included both tuber  cu-
lous pericarditis (n = 60) and PP (n = 34). Compared with 
tuberculous pericarditis, PP was 10 times (P  <0.0001) 
more likely to be associated with constrictive pericarditis 
on transthoracic echocardiography. Fibrinolysis lowered 
pericardial thickening, and decreased the rate of 
constrictive pericarditis by 38.3% (hazard ratio = 0.185, 
P <0.0001). Th   e length of evolution of the disease before 
treatment was also predictive of constrictive pericarditis. 
Interestingly, the rate of constrictive pericarditis was 
much higher than in previous reports (3.5% vs. 57% in 
placebo group), but follow-up was much longer. Con-
stric  tion occurred with a mean delay of 11 months. We 
cannot draw any deﬁ  nitive conclusion from this study 
since no subgroup analysis was performed in the PP 
population.
Timing of fi  brinolysis in PP
Th  ere is no consensus on the appropriate timing of 
ﬁ   brino  lysis (Table 5). Two main options can be 
distinguished: primary ﬁ   brinolysis performed immedi-
ately after drain insertion, and rescue ﬁ  brinolysis applied 
in cases of recurrence or incomplete evacuation of pus. 
Among published articles, we only found cases of failure 
when ﬁ  brinolysis had been applied late. At this stage, 
Table 4. Outcome according to management with primary 
pericardiectomy or pericardiocentesis
 Mortality
Reference Pericardiectomy  Pericardiocentesis
[4]a –  5/11  (45)
[27]b 0/4  (0)  –
[29]c  8/50 (16)  20/31 (65)
[25]d 1/13  (8)  –
[10]e  0/1 (0)  3/14 (21)
Data presented as n (%). aPericardiocentesis: rescue pericardiectomy in four 
cases (all survivors). bPericardiectomy. cWindow pericardiectomy and manual 
breakdown of adhesions. dPartial pericardiectomy. ePericardiocentesis: rescue 
pericardiectomy in six cases (fi  ve survivors).
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Page 5 of 8thick loculations cannot be liqueﬁ  ed by ﬁ  brinolytic agent 
[40,42] (Table 5). Furthermore, ﬁ   brinolytic agents can 
only dissolve ﬁ  brin, but have no eﬀ  ect on ﬁ  brosis. Two 
experimental studies indicate that ﬁ  brin inﬂ  ux increases 
during the ﬁ  rst week of the disease and that ﬁ  brosis may 
appear after 2 weeks [20,21]. Th  ese studies suggest that 
earlier administration may lead to optimal outcomes. 
Nevertheless, data regarding optimal timing are solely 
based on animal models and on a few case reports, limiting 
the ability to make a deﬁ  nitive statement.
Optimal fi  brinolytic dose and volume
SK, UK and tPA have all been used in pericardial ﬁ  brino-
lysis. Dose comparison between tPA and UK found an 
equivalence of 36,000 units UK for 1 mg tPA [49]. Most 
studies of ﬁ  brinolysis in PP used SK. Because of the risk 
of allergy, however, using UK or tPA has been suggested 
[50]. Owing to the lack of guidelines, there is large 
variability in ﬁ  brinolytic dosing in the reported cases. UK 
was used at a dose of 400,000 units in four cases and 
200,000 units in another study, diluted in 20 ml normal 
saline. Th  e British Th  oracic Society guidelines for the 
management of pleural infection propose instillation of 
250,000 UI SK daily or twice daily or of 100,000 UI UK 
daily [24]. A dose of 10 mg tPA has been proposed in 
empyema [51]. Th  ere are no deﬁ   nitive data on the 
appropriate dose of these three ﬁ  brinolytic agents. Given 
the diﬀ  erent regi  mens previously used in PP (Table 5) 
and the doses proposed by the British Th  oracic Society 
and the Ameri  can Th   oracic Society for treating empyema, 
Figure 2. Flow diagram describing the proposed algorithm for diagnosis and management of purulent pericarditis. *In relation to 
aetiologic classifi  cation (Table 1). **If no haemorrhagic complication of pericardial drainage. +If catheter/drain is permeable. PP, purulent pericarditis.
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Page 6 of 8reason  able options may be daily instillations of 
250,000  UI  SK, 200,000  UI  UK or 10  mg tPA. Each 
instillation should be diluted in a volume of at least 20 ml 
normal saline to ensure adequate diﬀ   usion into the 
pericardial space. Fibrinolytic agents must be retained in 
the pericardial space by clamping the drain for 2 to 4 
hours. Treatment may be repeated for three consecutive 
days to achieve complete pericardial drainage, assessed 
by echocardiography (Figure 2).
Failure and complications of fi  brinolysis
In case of ﬁ   brinolysis failure, resulting in incom  plete 
drainage despite three consecutive instillations of 
ﬁ   brinolytic agent associated with adequate antibio-
therapy, a surgical approach should be considered. Given 
the prognosis and the general status of the patient, radical 
pericardiectomy should only be performed if its beneﬁ  ts 
are believed to outweigh the potential drawbacks.
Th  ree complications of ﬁ   brinolysis can theoretically 
occur. Even if allergy is a well-known side eﬀ  ect  of 
ﬁ   brinolysis after repeated instillation of SK, treatment 
with UK or tPA greatly reduces this risk [50]. Th  e  second 
risk is major haemorrhage. Only one case of haemor-
rhagic tamponade after ﬁ  brinolysis has been described 
[39]. Th   is could be a consequence of PP and not directly 
related to ﬁ  brinolysis. Fibrinolysis for empyema is not 
associated with bleeding events [33,35]. Indeed, ﬁ  brino-
lysis in PP has no systemic eﬀ  ect detected on coagulation 
laboratory tests [28]. Th   e third risk is cardiac tamponade, 
which could occur if the instilled volume is not evacuated 
by the pericardial drain. Th  e pressure–volume curve 
(Figure 3) described in the experimental study published 
by Refsum and colleagues illustrates that the addition of a 
small volume of liquid may provoke cardiac compression 
[52]. Th   is risk could be increased in the later stage of the 
disease, characterised by low pericardial compliance 
secondary to ﬁ   brosis. In fact, no tamponade due to 
intrapericardial administration of ﬁ   brinolysis has been 
described. Th   e risk of tamponade could be lowered if the 
volume of ﬁ  brinolytic agent instilled is inferior to the 
amount of ﬂ  uid drained immediately beforehand.
Deﬁ  nitive conclusions on the risks and complications 
of intrapericardial ﬁ  brinolysis cannot be made with the 
evaluation of 74 case reports. Potential beneﬁ  ts  of 
ﬁ  brinolysis seem to outweigh its apparent low morbidity.
Conclusion
PP managed with simple pericardial drainage may evolve 
to constrictive and persistent PP. Despite the lack of 
deﬁ  nitive evidence, intrapericardial ﬁ  brinolysis may be 
an alternative to pericardiectomy as a treatment for PP 
and for prevention of persistent PP and constrictive 
pericarditis. Clinical and experimental data demonstrate 
that features of irreversible ﬁ   brosis may appear after 
2  weeks. Considering that diagnosis of PP is often 
delayed, early consideration should therefore be given to 
ﬁ  brinolysis to ensure optimal eﬃ   cacy. Complications of 
intrapericardial ﬁ  brino  lysis have only exceptionally been 
reported. Physicians should thus not be reluctant to apply 
this promising technique. Nevertheless, in cases of failure 
of ﬁ   brinolysis, pericardiectomy remains the primary 
option to consider for complete eradication of infection 
and prevention of persistent PP and constrictive 
pericarditis.
Abbreviations
PP, purulent pericarditis; RCT, randomised controlled trial; SK, streptokinase; 
tPA, tissue plasminogen activator; UK, urokinase.
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